Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Uncovering the genetic diversity of the malaria parasite antigen MSP2 across Sub-Saharan Africa

Zerebinski J. et al, (2025)

Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to Shigella

Randall AZ. et al, (2025), MSPHERE

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.

Kibwana E. et al, (2025), Front Immunol, 16

Reversible host cell surface remodelling limits immune recognition and maximizes survival of Plasmodium falciparum gametocytes

Ngotho P. et al, (2025), PLOS PATHOGENS, 21

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.

Bundi C. et al, (2025), Front Immunol, 16

Antibodies to PfEMP1 and variant surface antigens: Protection after controlled human malaria infection in semi-immune Kenyan adults.

Kinyua AW. et al, (2024), J Infect, 89

R21 malaria vaccine is protective against intradermal but not intravenousPlasmodium falciparumsporozoites in a randomized controlled human malaria infection study in Kenyan adults

Kapulu MC. et al, (2024)

Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.

Rosenkranz M. et al, (2024), Life Sci Alliance, 7

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.

Nkumama IN. et al, (2024), Immunity, 57, 1215 - 1224.e6

Reversible host cell surface remodelling limits immune recognition and maximizes transmission ofPlasmodium falciparumgametocytes

Ngotho P. et al, (2024)

Social, Ethical and Regulatory implications of conducting a malaria Vaccine Efficacy trial in a human infection study in Kenya (SERVE-Kenya): A study protocol

Chi PC. et al, (2024), Wellcome Open Research, 9, 193 - 193

Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.

Kapulu M. et al, (2024), Biologicals, 85

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.

Kapulu MC. et al, (2024), Front Immunol, 15

Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.

Kibwana E. et al, (2024), 445, 337 - 365

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023

Cavaleri M. et al, (2024), Biologicals

Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.

Barnes MVC. et al, (2023), Immunother Adv, 3

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.

Sang S. et al, (2023), Wellcome open research, 8

Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia

Kunda-Ng'andu EM. et al, (2021)

Include forthcoming?